Cocrystal Pharma, Inc. Common Stock
COCPCocrystal Pharma, Inc. (COCP) is a biotechnology company focused on developing antiviral therapeutics and diagnostics. It leverages its expertise in structure-based drug design and proprietary platforms to create treatments for viral infections such as hepatitis, influenza, and COVID-19. The company's approach combines scientific innovation with targeted antiviral development to address significant unmet medical needs.
Company News
Cocrystal Pharma completed enrollment in the first cohort of a Phase 1b challenge study for CDI-988, an oral protease inhibitor for norovirus prevention and treatment. The company received FDA Fast Track designation for CDI-988 and an initial $225,000 NIH SBIR grant for influenza A/B antiviral development. Q1 2026 revenue was $225,000 from grant ...
Cocrystal Pharma announced that its oral norovirus protease inhibitor CDI-988 will be presented at the ICAR 2026 conference in Prague. The company will present Phase 1 data and updates from an ongoing Phase 1b challenge study at Emory University School of Medicine. CDI-988 is the first oral antiviral drug candidate being developed for prevention ...
Cocrystal Pharma presented CDI-988, a potential first oral antiviral for norovirus infection, at the International Calicivirus Conference. The drug shows promising broad-spectrum activity and has received FDA clearance for a Phase 1b human challenge study.
Cocrystal Pharma's CFO and co-CEO James Martin will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference, discussing their clinical-stage antiviral drug development efforts.
Cocrystal Pharma is extending enrollment in a Phase 2a study of its influenza antiviral candidate CC-42344 due to unexpectedly low influenza infection rates among study participants. The drug showed a favorable safety and tolerability profile, but the low infection rates hindered the analysis of its antiviral activity.
